Clinical and epidemologic relevance of HPV in Penile Cancer: a retrospective study

• Autor(a) principal: Ana Rita Macieira Marques
• Data de Publicação: 2023
• Tipo de documento: Dissertação
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://hdl.handle.net/10216/150266
• topic: Medicina clínica; Clinical medicine

Background: Penile cancer is rising in most European countries. Several risk factors have been identified, namely human papillomavirus (HPV) infection. However, the exact role of HPV in penile cancer carcinogenesis is still unknown. Clarifying the contribution of HPV in penile cancer is crucial as it may improve prevention and treatment strategies. Objectives: The aim of this study is to describe the characteristics of patients with penile cancer and penile intraepithelial neoplasia (PeIN), evaluate the prevalence of HPV-DNA in tumor tissue, and identify differences between patients with and without HPV-DNA. Methods: A retrospective observational study including patients with histological diagnosis of penile squamous cell carcinoma (SCC) or PeIN between 2012 and 2021 in a university hospital was carried out. HPV analysis was performed using CLART Papillomavirus, for the detection and typing of 28 types of HPV in tissue specimens. Results: A total of 25 patients were included. Most of the tumors identified were invasive SCC (n=11) and SCC in situ (PeIN 3) (n= 8). HPV-DNA was tested in all tissue specimens and was detected in 18 of them. High risk HPV DNA was identified in all positive HPV samples, except one. HPV types included in the nonavalent HPV vaccine were identified in 16 of the 18 samples positive for HPV-DNA. Stratifying patients according to HPV-DNA detection, we found that patients with HPV-DNA were younger (57.5 years vs. 70 years, p=0.047), less likely to have phimosis (5.8% vs. 42.9%, p=0.022) and more likely to have PeIN lesions than invasive SCC (85.7% vs. 27.8%, p=0.025 ). Conclusion: This study shows a prevalence of HPV-DNA in penile SCC and premalignant lesions of 45.5% and 92.9%, respectively. Identifying HPV involvement in SCC and PeIN pathology has the potential to guide treatment and enhance follow-up strategies. The neutral-gender HPV vaccine impact assessment on penile cancer in ongoing.